The results indicated that individuals with TP53 mutations were more susceptible to most medications with lower 50% inhibitory concentration (IC50) values, such as lapatinib, docetaxel, and erlotinib (Fig. 3A), all of which are often used in cancer treatment. Here, TP53 is linked to cancer.